Danoprevir: First Global Approval

Markham, Anthony; Keam, Susan J.

doi:10.1007/s40265-018-0960-0

Cited by 37 publications

(29 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Danoprevir is an HCV NS3 protease inhibitor approved in China for the treatment of non-cirrhotic genotype 1b chronic hepatitis C, in combination with ritonavir, peginterferon-a, and ribavirin (41).…”

Section: Resultsmentioning

confidence: 99%

Clinical trials on drug repositioning for COVID-19 treatment

Rosa

Santos

2020

Revista Panamericana De Salud Pública

371

307

View full text Add to dashboard Cite

The World Health Organization (WHO) was informed on December 2019 about a coronavirus pneumonia outbreak in Wuhan, Hubei province (China). Subsequently, on March 12, 2020, 125,048 cases and 4,614 deaths were reported. Coronavirus is an enveloped RNA virus, from the genus Betacoronavirus, that is distributed in birds, humans, and other mammals. WHO has named the novel coronavirus disease as COVID-19. More than 80 clinical trials have been launched to test coronavirus treatment, including some drug repurposing or repositioning for COVID-19. Hence, we performed a search in March 2020 of the clinicaltrials.gov database. The eligibility criteria for the retrieved studies were: contain a clinicaltrials.gov base identifier number; describe the number of participants and the period for the study; describe the participants' clinical conditions; and utilize interventions with medicines already studied or approved for any other disease in patients infected with the novel coronavirus SARS-CoV-2 (2019-nCoV). It is essential to emphasize that this article only captured trials listed in the clinicaltrials.gov database. We identified 24 clinical trials, involving more than 20 medicines, such as human immunoglobulin, interferons, chloroquine, hydroxychloroquine, arbidol, remdesivir, favipiravir, lopinavir, ritonavir, oseltamivir, methylprednisolone, bevacizumab, and traditional Chinese medicines (TCM). Although drug repurposing has some limitations, repositioning clinical trials may represent an attractive strategy because they facilitate the discovery of new classes of medicines; they have lower costs and take less time to reach the market; and there are existing pharmaceutical supply chains for formulation and distribution.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical trials on drug repositioning for COVID-19 treatment

Rosa

Santos

2020

Revista Panamericana De Salud Pública

371

307

View full text Add to dashboard Cite

show abstract

“…Clinical trials to assess the effects of the combination of 200 with the NS5A replication complex inhibitor ravidasvir are ongoing. [72][73][74][75][76][77][78] The discovery synthesis of 200 is depicted in Scheme 23 and beginsw ith coupling of the P1 element 202,w hich is resolved through an enzyme-based procedure, with tBoc-protected 4hydroxyproline (203)m ediated by HATU and Hünig's base in DMF to afford 204 in 80 %y ield. The Boc protecting group was removed from 204 and the amine was acylated with (R)-2-[(tert-butoxycarbonyl)amino]non-8-enoic acid (205)b yu sing HATU and Hünig's base in DMF to give diene 206.T he P1-P3 macrocyclic linker was establishedb ym eanso faring-closing metathesis (RCM) reaction mediated by the Hoveyda first-generation catalyst (207)t oa fford 208 in 52 %y ield after chromatographic purification.…”

Section: Danoprevirmentioning

confidence: 99%

Tailor‐Made Amino Acids and Fluorinated Motifs as Prominent Traits in Modern Pharmaceuticals

Mei

Han

White

et al. 2020

Chemistry A European J

View full text Add to dashboard Cite

Structural analysis of modern pharmaceutical practices allows for the identification of two rapidly growing trends: the introduction of tailor‐made amino acids and the exploitation of fluorinated motifs. Curiously, the former represents one of the most ubiquitous classes of naturally occurring compounds, whereas the latter is the most xenobiotic and comprised virtually entirely of man‐made derivatives. Herein, 39 selected compounds, featuring both of these traits in the same molecule, are profiled. The total synthesis, source of the corresponding amino acids and fluorinated residues, and medicinal chemistry aspects and biological properties of the molecules are discussed.

show abstract

“…On the other hand, in a molecular docking simulation study, simeprevir has a stronger interaction with connecting receptors than lopinavir/ritonavir, which is commonly used in different SARS-CoV2 treatment regimens [114]. The anti-viral mechanism of simeprevir and danoprevir is similar [115]. Recently, danoprevir was approved in China for the treatment of treatment-naive patients with non-cirrhotic genotype 1b chronic hepatitis C. It has also shown potent and broad-spectrum anti-viral effects on hepatitis C [116].…”

Section: Danoprevirmentioning

confidence: 99%

Pharmacological treatments of COVID-19

et al. 2020

View full text Add to dashboard Cite

The viral infection due to the new coronavirus or coronavirus disease 2019 (COVID-19), which was reported for the first time in December 2019, was named by the World Health Organization (WHO) as Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV2), because of the very similar genome and also its related symptoms to SARS-CoV1. The ongoing COVID-19 pandemic with significant mortality, morbidity, and socioeconomic impact is considered by the WHO as a global public health emergency. Since there is no specific treatment available for SARS-CoV2 infection, and or COVID-19, several clinical and sub-clinical studies are currently undertaken to find a gold-standard therapeutic regimen with high efficacy and low side effect. Based on the published scientific evidence published to date, we summarized herein the effects of different potential therapies and up-to-date clinical trials. The review is intended to help readers aware of potentially effective COVID-19 treatment and provide useful references for future studies.

show abstract

Danoprevir: First Global Approval

Cited by 37 publications

References 17 publications

Clinical trials on drug repositioning for COVID-19 treatment

Clinical trials on drug repositioning for COVID-19 treatment

Tailor‐Made Amino Acids and Fluorinated Motifs as Prominent Traits in Modern Pharmaceuticals

Pharmacological treatments of COVID-19

Contact Info

Product

Resources

About